Last Updated: September 24, 2026

ELIGARD Drug Patent Profile

Name: ELIGARD Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Eligard patents expire, and what generic alternatives are available?

Eligard is a drug marketed by Tolmar and is included in four NDAs. There are three patents protecting this drug.

The generic ingredient in ELIGARD is leuprolide acetate. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eligard

A generic version of ELIGARD was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ELIGARD?
What are the global sales for ELIGARD?
What is Average Wholesale Price for ELIGARD?

Summary for ELIGARD

US Patents:	0
Applicants:	1
NDAs:	4
Drug Prices:	Drug price information for ELIGARD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ELIGARD
What excipients (inactive ingredients) are in ELIGARD?	ELIGARD excipients list
DailyMed Link:	ELIGARD at DailyMed

Drug patent expirations by year for ELIGARD

Recent Clinical Trials for ELIGARD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ontario Clinical Oncology Group (OCOG) - McMaster University	PHASE2
Ontario Clinical Oncology Group (OCOG)	PHASE2
TOLMAR PHARMACEUTIQUES CANADA, INC.	PHASE2

See all ELIGARD clinical trials

US Patents and Regulatory Information for ELIGARD

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021343-001	Jan 23, 2002		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021488-001	Feb 13, 2003		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Tolmar	ELIGARD KIT	leuprolide acetate	POWDER;SUBCUTANEOUS	021379-001	Jul 24, 2002		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for ELIGARD

Eligard 3 month dose cost?
Eligard generic?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.